Pfizer Inc. (PFE)
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent litigation UK trial on validity of intellectual property rights EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A tail technology) began July 10; judgement expected later in 2024 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 11, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the latest trial dates for its ongoing patent litigation against Pfizer/BioNTech in multiple geographies including the U.S., UK and Germany.
Pfizer moves forward with once-daily version of weight loss pill after setbacks
Pfizer said it will continue to develop the once-daily version of its weight loss pill, danuglipron, after it saw "encouraging" data in an early-stage trial. The company plans to conduct studies in the second half of the year evaluating multiple doses of the drug.
Pfizer moves forward with once-daily weight loss pill
Pfizer said on Thursday it would advance a reworked, once-a-day version of its experimental obesity pill, danuglipron to clinical trials in the second half of this year, sending its shares 5% higher in premarket trading.
Evotec and Pfizer Collaborate to Advance Drug Discovery in France
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases.
Pfizer: Buy This Big Yielder On The Strong Pipeline
Pfizer's cash flow from operations in 2022 was $29.267 billion, driven by COVID-19 vaccine and Paxlovid sales, but dropped to $8.7 billion in 2023. Despite revenue loss from COVID-19 drugs, the Company has a strong drug pipeline and scale advantage over rivals. Facing patent expirations and challenges from the US Inflation Reduction Act, PFE focuses on oncology drugs, biologics, and future revenue growth.
Pfizer's longtime science chief Mikael Dolsten to step down
Pfizer said on Tuesday its chief scientific officer Mikael Dolsten, a key figure behind the development of the company's COVID-19 vaccine, would step down after a more than 15-year career at the drugmaker.
Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
Pfizer (PFE) concluded the recent trading session at $27.93, signifying a -0.43% move from its prior day's close.
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births
Pfizer's respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots.
Pfizer: The Inflection Point Is Here
Pfizer's recent financial performance and Wall Street analysts' expectations around the upcoming quarterly earnings release suggest that we are currently at an inflection point. The company's current pipeline of new product developments looks promising, and two recent FDA approvals underscore its ability to deliver new products to the market. I expect more full-year EPS guidance upgrades soon, as it appears that the company is moving ahead of management's initial cost-cutting plans.
Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock
Much of Pfizer's revenue is driven by therapies with only modest competition. This stock is also developing a very impressive dividend-growth track record.
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
Despite a tanking stock price, Pfizer has raised its dividend for 15 consecutive years. Pfizer's profits are off their peak but more than sufficient to continue raising the dividend.
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
